In this MA, led by Jasna Deluce and David Maj, we concluded that combined inhibition of EGFR and VEGF improves PFS. No OS benefit. Increases AEs. Further exploration of this strategy with 3rd generation EGFR TKIs is needed. journals.lww.com/amjclinicalonc…

Great talks today at the 4th Annual Immuno-Oncology Symposium CTCR #CTCRIO2023

Just published in Current Oncology MDPI ! We review one of the most exciting topics in GU oncology, triplet therapy in mCSPC. A huge thank you to Maria Jiang, KSridhar and Dr. Micheal Ong for support You can read it here. mdpi.com/1718-7729/30/4…

Sharing our review discussing efficacy, safety and future with ADCs in NSCLC - ‘Targeting’ Improved Outcomes with Antibody-Drug Conjugates in Non-Small Cell Lung Cancer—An Updated Review mdpi.com/2256206 #mdpicurroncol via Current Oncology Jacques Raphael Dr. Daniel Breadner

Adjuvant osimertinib is now a standard of care in patients w/resected stage IB-IIIA NSCLC harboring an activating EGFR mutation. Review covers data on adjuvant EGFR TKIs, evidence of benefits conferred & limitations, and variability in endpoints used. ja.ma/3O0AhHi

Happy to share our recently published article. Addition of metformin to chemotherapy doesn’t improve outcomes in advanced NSCLC. Does it have meaningful anti cancer effect with other combinations or in other settings? It remains unanswered. rdcu.be/ddzb6

Here is an inexpensive and highly useful MRD technique using ddPCR in EGFR mutated resectable NSCLC. Could it replace CT scans or perhaps reduce their frequency? Particularly important given young age of this population! #LCSM jto.org/article/S1556-…

Antibody–Drug Conjugates in Breast Cancer: Ascent to Destiny and Beyond—A 2023 Review An excellent review👇 Current Oncology mdpi.com/2375694

Hot off the press in NatureRevClinOncol ! Using examples from trials presented at #ASCO23, in this educational piece, I highlight how we should think about crossover in cancer clinical trials. Such education also forms a core theme of what we do Common Sense Oncology. In this piece, I argue

Sharing our review discussing the role of consolidative TRT in ES-SCLC in the era of immunotherapy. We need to find the appropriate population, dose and timing of TRT. doi.org/10.1177/175883…

Detection of Circulating Tumor DNA after Stereotactic Ablative Radioth... sciencedirect.com/science/articl… Dr. Daniel Breadner David Palma, MD, PhD Sympascho Young MD

Immunotherapy and Radiation therapy Sequencing in Breast Cancer: A Systematic Review - International Journal of Radiation Oncology, Biology, Physics redjournal.org/article/S0360-… Joelle Sympascho Young MD Jacques Raphael

Warm welcome to our new #BMCCancer Editorial Board Member Saurav Verma. We look forward to working with you! Interested in joining #BMCCancer? Visit <bmccancer.biomedcentral.com/join-our-edito…>.

Delighted to share this recent publication in IJROBP - The Red Journal on sequencing of immunotherapy and radiation in breast cancer, co-authored with talented med onc fellow Saurav Verma and PIs Joelle Jacques Raphael authors.elsevier.com/c/1iWVK1Hx52Jt…

Sharing our review article on Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy. We discuss the evidence and unanswered questions in this space. mdpi.com/2729712 #mdpicancers #lcsm Dr. Daniel Breadner Jacques Raphael Abhenil Mittal David Palma, MD, PhD

🎖️Check out the Editor's Choice #Review "An Updated Review of Management of Resectable Stage III NSCLC in the Era of Neoadjuvant Immunotherapy" 👏by Saurav Verma, et al. Western University 📌Link here: mdpi.com/2072-6694/16/7…

Presented our poster on interim results of SABR-DETECT. Rate of ctDNA detection increased by testing post-SABR samples in early-stage NSCLC. Liquid biopsy can be useful in confirming diagnosis in presumed NSCLC treated with radiation. #ISLB24 International Society of Liquid Biopsy Geneseeq Technology Inc.

"Young Onset Lung Cancer in India: Insights into Clinical, Demographic, and Genomic Profiles" - Clinical Lung Cancer clinical-lung-cancer.com/article/S1525-…. Happy to share our recent paper highlighting the profile of young onset LC which is otherwise rare.

Honored to present updated results of SABR-DETECT as a poster at #ASCO25 and receive the Conquer Cancer Merit Award. Thank you Conquer Cancer, the ASCO Foundation and my incredible mentors for support. Geneseeq Technology Inc.

Our latest review on EGFR-mutated advanced NSCLC is out! We cover new data, challenges in resistance, and emerging treatments. doi.org/10.3390/curron… Thanks to all the mentors for their guidance. Abhenil Mittal #EGFR #NSCLC #CancerResearch #PrecisionOncology #FLAURA2 #MARIPOSA